

Revolade Tablets Specified Drug-use Survey

NCT06287268

Status RECRUITING
Sponsor Novartis Pharmaceuticals
Enrollment 10 participants

Key Eligibility Criteria

Inclusion (3)

- Patients whose legally acceptable representative has given written consent for cooperation in this survey prior to enrollment in this survey
- Patients aged ≥ 6 years and < 18 years at the start of treatment with eltrombopag
- Pediatric patients with AA who receive eltrombopag for the first time in combination with ATG after the approval of additional dosage and administration for "ATG-naïve pediatric patients with AA"

Exclusion (4)

- Patients who have received ATG without concomitant use of eltrombopag
- Patients with congenital AA
- Patients with suspected or confirmed diagnosis of myelodysplastic syndrome (MDS) at the start of treatment with eltrombopag
- Patients who have received any drug products containing the same ingredient as eltrombopag (including investigational products)

Locations (17 total)

Novartis Investigative Site, Nagoya, Aichi-ken, Japan
Novartis Investigative Site, Nagoya, Aichi-ken, Japan
Novartis Investigative Site, Toyoake, Aichi-ken, Japan
... and 14 more locations

<https://clinicaltrials.gov/study/NCT06287268>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).